Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On January 28, 2026, he acquired 6 shares of common stock at $183.51 per share. Following this routine reinvestment, he directly owns 2,704 shares of Quest Diagnostics common stock. The transaction was eligible for later reporting on Form 5, but he chose to report it early on this Form 4.
Quest Diagnostics director Vicky B. Gregg reported a small automatic share acquisition. On January 28, 2026, she acquired 67 shares of common stock at $183.513 per share through a broker-administered dividend reinvestment plan, bringing her direct holdings to 17,104 shares. The transaction was voluntarily reported early on Form 4, even though it was eligible for deferred reporting on Form 5 under Rule 16a-6.
DGX reported a Form 144 notice relating to proposed or completed sales of common stock by an insider. The filing shows a reported sale of 5,662 shares on 02/10/2026 for $1,155,048.00. The filing also lists restricted stock vesting of 436 shares on 02/12/2026 and 522 shares on 02/14/2026.
Quest Diagnostics reported an insider sale and recent restricted stock vesting. Catherine T. Doherty sold 26,165 Common shares on 02/13/2026 for $5,393,815.32. The filing also lists restricted stock vesting of 726 shares on 02/12/2026 and 707 shares on 02/14/2026, each labeled as Issuer compensation.
DGX filed a Form 144 indicating planned sales of common stock following restricted stock vesting. The notice lists 480 shares with a 02/12/2026 date and 631 shares with a 02/14/2026 date, with transactions routed through Fidelity Brokerage Services LLC.
Quest Diagnostics EVP Catherine T. Doherty reported an option exercise and related share sales. On 02/13/2026 she exercised 26,165 non-qualified stock options at $112.17 per share, receiving the same number of common shares.
That day she sold 26,165 common shares in several open-market transactions at weighted average prices between $205.2072 and $209.1024, under a pre-established Rule 10b5-1 sales plan. After these transactions, she held 68,068 common shares directly and 4,503 shares indirectly through a 401(k)/deferred compensation plan.
A shareholder of DGX has filed a notice under Rule 144 to sell 26,165 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/13/2026. The filing lists an aggregate market value of these shares of 5428714.20. The shares were acquired on 02/13/2026 by exercising stock options that were originally granted on 02/18/2020, with payment in cash. The notice states that 111,242,362 shares of the issuer’s common stock were outstanding, providing context for the planned transaction.
Quest Diagnostics executive Patrick Plewman reported multiple stock transactions involving DGX shares. On January 28, 2026, he acquired 48 shares of common stock at $183.512 per share through a dividend reinvestment plan administered by his broker, bringing direct ownership to 15,381 shares.
On February 10, 2026, he exercised a non-qualified stock option for 5,662 shares of common stock at an exercise price of $121.805 per share and immediately sold 5,662 shares of common stock at $204 per share in an open-market transaction. After these transactions, he directly owned 15,381 shares of Quest Diagnostics common stock. The filing notes that the option exercise and sale were carried out under a pre-arranged Rule 10b5-1 sales plan.
A holder of DGX common stock has filed a notice of intent to sell 5,662 shares under Rule 144. The planned sale, through Fidelity Brokerage Services LLC on the NYSE, has an stated aggregate market value of $1,155,048.00.
The shares are part of DGX common stock, with 111,242,362 shares outstanding at the time referenced. The seller acquired these 5,662 shares on 02/10/2026 by exercising a stock option originally granted on 02/17/2021, and paid the purchase price in cash.
A holder of DGX common stock has filed a notice of intent to sell 5,662 shares under Rule 144. The planned sale, through Fidelity Brokerage Services LLC on the NYSE, has an stated aggregate market value of $1,155,048.00.
The shares are part of DGX common stock, with 111,242,362 shares outstanding at the time referenced. The seller acquired these 5,662 shares on 02/10/2026 by exercising a stock option originally granted on 02/17/2021, and paid the purchase price in cash.
Quest Diagnostics reported strong 2025 results with net revenues of $11.04 billion, up 11.8% from 2024, and reported diluted EPS of $8.75, up 13.8%. Adjusted diluted EPS was $9.85, up 10.3%. Fourth quarter revenue rose 7.1% to $2.81 billion, with diluted EPS of $2.18 and adjusted diluted EPS of $2.42. Cash from operations for 2025 was $1.89 billion.
The company issued 2026 guidance for net revenues of $11.70–$11.82 billion, reported diluted EPS of $9.45–$9.65, and adjusted diluted EPS of $10.50–$10.70. The Board raised the quarterly dividend 7.5% from $0.80 to $0.86 per share, or $3.44 annually, and expanded the share repurchase authorization by $1 billion, on top of approximately $0.4 billion remaining as of December 31, 2025.
Quest Diagnostics reported strong 2025 results with net revenues of $11.04 billion, up 11.8% from 2024, and reported diluted EPS of $8.75, up 13.8%. Adjusted diluted EPS was $9.85, up 10.3%. Fourth quarter revenue rose 7.1% to $2.81 billion, with diluted EPS of $2.18 and adjusted diluted EPS of $2.42. Cash from operations for 2025 was $1.89 billion.
The company issued 2026 guidance for net revenues of $11.70–$11.82 billion, reported diluted EPS of $9.45–$9.65, and adjusted diluted EPS of $10.50–$10.70. The Board raised the quarterly dividend 7.5% from $0.80 to $0.86 per share, or $3.44 annually, and expanded the share repurchase authorization by $1 billion, on top of approximately $0.4 billion remaining as of December 31, 2025.